FluoGuide is trading 9.5% up at SEK 36.90, but the catalyst is unconfirmed.

  • The market is closed, so this is not a confirmed October 6 closing price.
  • On October 5, FluoGuide announced that the first patient had enrolled in its U.S. Phase 2 FG001 trial for high-grade glioma.
  • This milestone was for its first trial under its U.S. IND application; the announcement did not explicitly link it to the share move.